CHAMP - Chippewa Homestead Antenna & Mission Program

On January 28, 2021 the Michigan Aerospace Manufacturing Association (MAMA) announced the site selection for the Michigan Launch Initiative (MLI) Satellite Command and Control Communications (C3) center. The Chippewa Homestead Antenna & Mission Program (CHAMP) was selected to host, implement, and conduct the C3 functions for MLI\u27s vertical and horizontal launch capabilities. This poster presents in detail the CHAMP phased implementation strategy to support the complex mission operations needs of the next generation Hybrid Architectures and Mesh Networks

Enabling Hybrid Architectures and Mesh Network Topologies to Support the Global Multi-Domain Community

The turn of the new decade also represents the dawn of a new shift in domain operations. Concepts such as “Space Dial Tone,” reliable global access to internet, on-demand Earth observation, and remote sensing, while still not fully realized, are no longer purely imaginative. These concepts are in high demand and are coupled with the goals of Global Multi-Domain Operations (MDO). Small satellites (smallsats) have emerged as functionally reliable platforms, driving the development of next-generation satellite constellations. To achieve the potential of tomorrow’s technology, these constellations must embrace space mission architectures based on interoperable, open-system constructs such as hybrid architectures and mesh network topologies. This paper presents the full timeline for realization of multi-node, disparate (sovereign, coalition, commercial, etc.) multi-domain (Space, Air, Maritime, Land, and Cyber) systems to support future space mission architectures. It identifies and discusses the underlying technologies needed to bring new “system-of-systems” concepts to operational capability. Technologies to be discussed include: message-agnostic physical/protocol “Bridges”; Machine-to-Machine (M2M) data sharing enabled through Electronic Data Sheet (EDS) standards; and, new concepts related to Artificial Intelligence (AI) enabled human decision making. Tying these technologies together effectively will positively impact the smallsat market and fundamentally change mission architectures in the near future

Terrestrial ecological risk analysis via dietary exposure at uranium mine sites in the Grand Canyon watershed (Arizona, USA)

The U.S. Department of the Interior recently included uranium (U) on a list of mineral commodities that are considered critical to economic and national security. The uses of U for commercial and residential energy production, defense applications, medical device technologies, and energy generation for space vehicles and satellites are known, but the environmental impacts of uranium extraction are not always well quantified. We conducted a screening-level ecological risk analysis based on exposure to miningrelated elements via diets and incidental soil ingestion for terrestrial biota to provide context to chemical characterization and exposures at breccia pipe U mines in northern Arizona. Relative risks, calculated as hazard quotients (HQs), were generally low for all biological receptor models. Our models screened for risk to omnivores and insectivores (HQs\u3e1) but not herbivores and carnivores. Uranium was not the driver of ecological risk; arsenic, cadmium, copper, and zinc were of concern for biota consuming ground-dwelling invertebrates. Invertebrate species composition should be considered when applying these models to other mining locations or future sampling at the breccia pipe mine sites. Dietary concentration thresholds (DCTs) were also calculated to understand food concentrations that may lead to ecological risk. The DCTs indicated that critical concentrations were not approached in our model scenarios, as evident in the very low HQs for most models. The DCTs may be used by natural resource and land managers as well as mine operators to screen or monitor for potential risk to terrestrial receptors as mine sites are developed and remediated in the future

Assessment of Chronic Low-Dose Elemental and Radiological Exposures of Biota at the Kanab North Uranium Mine Site in the Grand Canyon Watershed

High-grade U ore deposits are in various stages of exploitation across the Grand Canyon watershed, yet the effects of U mining on ecological and cultural resources are largely unknown. Wecharacterized the concentrations of Al, As, Bi, Cd, Co, Cu, Fe, Pb, Hg, Mo, Ni, Se, Ag, Tl, Th, U, and Zn, gross alpha and beta activities, and U and Th radioisotopes in soil, vegetation (Hesperostipa comata, Artemisia tridentata, Tamarix chinensis), and rodents (Peromyscus maniculatus, P. boylii) to waste material at the Kanab North mine, a mine with decades-long surficial contamination, and compared the concentrations (P\u3c0.01) to those at a premining site (Canyon Mine). Rodent tissues were also analyzed for radium-226 and microscopic lesions. Radioactivities and some elemental concentrations (e.g., Co, Pb, U) were greater in the Kanab North mine biological samples than in Canyon Mine biota, indicating a mining-related elemental signature. Mean rodent Ra-226 (111 Bq/kg dry weight [dry wt]) was 3 times greater than expected, indicating radioactive disequilibrium. Multiple soil sample U concentrations exceeded a screening benchmark, growth inhibition thresholds for sensitive plants, and an EC20 for a soil arthropod. Lesions associated with metals exposure were also observed more frequently in rodents at Kanab North than those at Canyon Mine but could not be definitively attributed to U mining. Our results indicate that Kanab North biota have taken up U mining-related elements owing to chronic exposure to surficial contamination. However, no literature-based effects thresholds for small rodents were exceeded, and only a few soil and vegetation thresholds for sensitive species were exceeded; therefore, adverse effects to biota from U mining-related elements at Kanab North are unlikely despite chronic exposure

Elemental and radionuclide exposures and uptakes by small rodents, invertebrates, and vegetation at active and post-production uranium mines in the Grand Canyon watershed

The effects of breccia pipe uranium mining in the Grand Canyon watershed (Arizona) on ecological and cultural resources are largely unknown. We characterized the exposure of biota to uranium and cooccurring ore body elements during active ore production and at a site where ore production had recently concluded. Our results indicate that biota have taken up uranium and other elements (e.g., arsenic, cadmium, copper, molybdenum, uranium) from exposure to ore and surficial contamination, like blowing dust. Results indicate the potential for prolonged exposure to elements and radionuclides upon conclusion of active ore production. Mean radium-226 in deer mice was up to 4 times greater than uranium-234 and uranium-238 in those same samples; this may indicate a potential for, but does not necessarily imply, radium-226 toxicity. Soil screening benchmarks for uranium and molybdenum and other toxicity thresholds for arsenic, copper, selenium, uranium (e.g., growth effects) were exceeded in vegetation, invertebrates, and rodents (Peromyscus spp., Thomomys bottae, Tamias dorsalis, Dipodomys deserti). However, the prevalence and severity of microscopic lesions in rodent tissues (as direct evidence of biological effects of uptake and exposure) could not be definitively linked to mining. Our data indicate that land managers might consider factors like species, seasonal changes in environmental concentrations, and bioavailability, when determining mine permitting and remediation in the Grand Canyon watershed. Ultimately, our results will be useful for site-specific ecological risk analysis and can support future decisions regarding the mineral extraction withdrawal in the Grand Canyon watershed and elsewhere

Graphical Perception of Continuous Quantitative Maps: the Effects of Spatial Frequency and Colormap Design

Continuous 'pseudocolor' maps visualize how a quantitative attribute varies smoothly over space. These maps are widely used by experts and lay citizens alike for communicating scientific and geographical data. A critical challenge for designers of these maps is selecting a color scheme that is both effective and aesthetically pleasing. Although there exist empirically grounded guidelines for color choice in segmented maps (e.g., choropleths), continuous maps are significantly understudied, and their color-coding guidelines are largely based on expert opinion and design heuristics--many of these guidelines have yet to be verified experimentally. We conducted a series of crowdsourced experiments to investigate how the perception of continuous maps is affected by colormap characteristics and spatial frequency (a measure of data complexity). We find that spatial frequency significantly impacts the effectiveness of color encodes, but the precise effect is task-dependent. While rainbow schemes afforded the highest accuracy in quantity estimation irrespective of spatial complexity, divergent colormaps significantly outperformed other schemes in tasks requiring the perception of high-frequency patterns. We interpret these results in relation to current practices and devise new and more granular guidelines for color mapping in continuous maps

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.

BACKGROUND: In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis. We report results from a Phase 2 study and concurrent immuno-positron emission tomography (PET) study assessing efficacy, pharmacodynamics, pharmacokinetics, safety and cardiac uptake (of dezamizumab) following the same intervention in patients with cardiac amyloidosis. METHODS: Both were uncontrolled open-label studies. After SAP depletion with miridesap, patients received ≤ 6 monthly doses of dezamizumab in the Phase 2 trial (n = 7), ≤ 2 doses of non-radiolabelled dezamizumab plus [89Zr]Zr-dezamizumab (total mass dose of 80 mg at session 1 and 500 mg at session 2) in the immuno-PET study (n = 2). Primary endpoints of the Phase 2 study were changed from baseline to follow-up (at 8 weeks) in left ventricular mass (LVM) by cardiac magnetic resonance imaging and safety. Primary endpoint of the immuno-PET study was [89Zr]Zr-dezamizumab cardiac uptake assessed via PET. RESULTS: Dezamizumab produced no appreciable or consistent reduction in LVM nor improvement in cardiac function in the Phase 2 study. In the immuno-PET study, measurable cardiac uptake of [89Zr]Zr-dezamizumab, although seen in both patients, was moderate to low. Uptake was notably lower in the patient with higher LVM. Treatment-associated rash with cutaneous small-vessel vasculitis was observed in both studies. Abdominal large-vessel vasculitis after initial dezamizumab dosing (300 mg) occurred in the first patient with immunoglobulin light chain amyloidosis enrolled in the Phase 2 study. Symptom resolution was nearly complete within 24 h of intravenous methylprednisolone and dezamizumab discontinuation; abdominal computed tomography imaging showed vasculitis resolution by 8 weeks. CONCLUSIONS: Unlike previous observations of visceral amyloid reduction, there was no appreciable evidence of amyloid removal in patients with cardiac amyloidosis in this Phase 2 trial, potentially related to limited cardiac uptake of dezamizumab as demonstrated in the immuno-PET study. The benefit-risk assessment for dezamizumab in cardiac amyloidosis was considered unfavourable after the incidence of large-vessel vasculitis and development for this indication was terminated. Trial registration NCT03044353 (2 February 2017) and NCT03417830 (25 January 2018)

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.

BACKGROUND: In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis. We report results from a Phase 2 study and concurrent immuno-positron emission tomography (PET) study assessing efficacy, pharmacodynamics, pharmacokinetics, safety and cardiac uptake (of dezamizumab) following the same intervention in patients with cardiac amyloidosis. METHODS: Both were uncontrolled open-label studies. After SAP depletion with miridesap, patients received ≤ 6 monthly doses of dezamizumab in the Phase 2 trial (n = 7), ≤ 2 doses of non-radiolabelled dezamizumab plus [89Zr]Zr-dezamizumab (total mass dose of 80 mg at session 1 and 500 mg at session 2) in the immuno-PET study (n = 2). Primary endpoints of the Phase 2 study were changed from baseline to follow-up (at 8 weeks) in left ventricular mass (LVM) by cardiac magnetic resonance imaging and safety. Primary endpoint of the immuno-PET study was [89Zr]Zr-dezamizumab cardiac uptake assessed via PET. RESULTS: Dezamizumab produced no appreciable or consistent reduction in LVM nor improvement in cardiac function in the Phase 2 study. In the immuno-PET study, measurable cardiac uptake of [89Zr]Zr-dezamizumab, although seen in both patients, was moderate to low. Uptake was notably lower in the patient with higher LVM. Treatment-associated rash with cutaneous small-vessel vasculitis was observed in both studies. Abdominal large-vessel vasculitis after initial dezamizumab dosing (300 mg) occurred in the first patient with immunoglobulin light chain amyloidosis enrolled in the Phase 2 study. Symptom resolution was nearly complete within 24 h of intravenous methylprednisolone and dezamizumab discontinuation; abdominal computed tomography imaging showed vasculitis resolution by 8 weeks. CONCLUSIONS: Unlike previous observations of visceral amyloid reduction, there was no appreciable evidence of amyloid removal in patients with cardiac amyloidosis in this Phase 2 trial, potentially related to limited cardiac uptake of dezamizumab as demonstrated in the immuno-PET study. The benefit-risk assessment for dezamizumab in cardiac amyloidosis was considered unfavourable after the incidence of large-vessel vasculitis and development for this indication was terminated. Trial registration NCT03044353 (2 February 2017) and NCT03417830 (25 January 2018)

The James Webb Space Telescope Mission

Twenty-six years ago a small committee report, building on earlier studies, expounded a compelling and poetic vision for the future of astronomy, calling for an infrared-optimized space telescope with an aperture of at least $4m$. With the support of their governments in the US, Europe, and Canada, 20,000 people realized that vision as the $6.5m$ James Webb Space Telescope. A generation of astronomers will celebrate their accomplishments for the life of the mission, potentially as long as 20 years, and beyond. This report and the scientific discoveries that follow are extended thank-you notes to the 20,000 team members. The telescope is working perfectly, with much better image quality than expected. In this and accompanying papers, we give a brief history, describe the observatory, outline its objectives and current observing program, and discuss the inventions and people who made it possible. We cite detailed reports on the design and the measured performance on orbit.Comment: Accepted by PASP for the special issue on The James Webb Space Telescope Overview, 29 pages, 4 figure

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead